Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation.
In a single-center, randomized study, zanamivir (Relenza) concentrations in induced sputum samples and nasal washings of healthy adults following oral inhalation were measured. Concentrations in sputum exceeded the median viral neuraminidase 50% inhibitory concentration at 6, 12, and 24 h, and those in nasal washings did so at 6 and 12 h. There were no zanamivir-related adverse events or laboratory abnormalities.
Peng
A W
AW
Clinical Pharmacology Department, Glaxo Wellcome Inc., Research Triangle Park, North Carolina 27709, USA. ap4872@glaxowellcome.com
Milleri
S
S
Stein
D S
DS
D000280:Administration, Inhalation; D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects / Q000493:pharmacokinetics*; D005260:Female; D006146:Guanidines; D006801:Humans; D008297:Male; D017817:Nasal Lavage Fluid; D009439:Neuraminidase / Q000037:antagonists & inhibitors; D009975:Orthomyxoviridae / Q000187:drug effects / Q000201:enzymology; D011714:Pyrans; D012137:Respiratory System / Q000378:metabolism*; D012794:Sialic Acids / Q000009:adverse effects / Q000493:pharmacokinetics*; D013183:Sputum / Q000378:metabolism; D053243:Zanamivir
D000998:Antiviral Agents; D006146:Guanidines; D011714:Pyrans; D012794:Sialic Acids; D009439:Neuraminidase; D053243:Zanamivir